Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Major Depressive Disorder (MDD) AND Current Major Depressive Disorder AND Major Depressive Disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    157 result(s) found for: Major Depressive Disorder (MDD) AND Current Major Depressive Disorder AND Major Depressive Disorder. Displaying page 6 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2018-003573-97 Sponsor Protocol Number: PSIDER Start Date*: 2020-08-27
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London & Maudsley NHS Foundation Trust
    Full Title: A randomised, placebo controlled trial of psilocybin in treatment resistant depression: A feasibility study
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-003190-29 Sponsor Protocol Number: HMNC-101 Start Date*: 2012-01-30
    Sponsor Name:HolsboerMaschmeyer NeuroChemie (HMNC) GmbH
    Full Title: Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication according to the the ABCB1 Gene
    Medical condition: - Major Depression, single or recurrent, without psychotic features - Bipolar Disorders, currently depressed, without psychotic features
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    14.1 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    14.1 10037175 - Psychiatric disorders 10004940 Bipolar II disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001637-27 Sponsor Protocol Number: LQD Start Date*: 2016-09-20
    Sponsor Name:South London and Maudsley NHS Foundation Trust [...]
    1. South London and Maudsley NHS Foundation Trust
    2. King's College London
    Full Title: A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.
    Medical condition: Treatment resistant major depressive disorder (single episode or recurrent). Treatment resistant depression, defined as failure to respond to two or more adequate doses of antidepressant in the cur...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10067373 Depression perimenopausal LLT
    21.1 10037175 - Psychiatric disorders 10066555 Chronic depression LLT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012391 Depression postpartum (excl psychosis) LLT
    20.0 10022117 - Injury, poisoning and procedural complications 10012390 Depression postoperative PT
    20.0 10037175 - Psychiatric disorders 10012386 Depression mental LLT
    21.1 10037175 - Psychiatric disorders 10066530 Acute depression LLT
    20.0 10037175 - Psychiatric disorders 10012389 Depression postmenopausal LLT
    20.0 10037175 - Psychiatric disorders 10012387 Depression NOS LLT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    21.1 10037175 - Psychiatric disorders 10037998 Reactive depression LLT
    21.1 10037175 - Psychiatric disorders 10042457 Suicidal depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-018796-21 Sponsor Protocol Number: 31-08-255 Start Date*: 2010-11-02
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder.
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) EE (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001209-26 Sponsor Protocol Number: 01032012 Start Date*: 2013-10-11
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in...
    Medical condition: Major Depression ICD10: F 32.1, F 32.2, F32.3, F33.1, F33.2, F33.3 Klassifikationscode MedDRA : 10012378
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018858-12 Sponsor Protocol Number: 31-08-256 Start Date*: 2010-12-15
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder.
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Completed) SK (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005457-25 Sponsor Protocol Number: PCN-101-21 Start Date*: 2021-08-30
    Sponsor Name:Perception Neuroscience, Inc
    Full Title: A randomized, placebo-controlled, double-blind study to assess the safety and efficacy of intravenous PCN-101 in treatment-resistant depression
    Medical condition: Treatment-resistant depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018859-97 Sponsor Protocol Number: 31-08-263 Start Date*: 2010-10-04
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder.
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) ES (Prematurely Ended) HU (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004585-22 Sponsor Protocol Number: ESKETINTRD3002 Start Date*: 2015-08-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult S...
    Medical condition: Treatment-resistant Major Depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-004829-33 Sponsor Protocol Number: 17797A Start Date*: 2018-10-03
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label, flexible-dose study of vortioxetine on emotional functioning in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment
    Medical condition: Emotional functioning in patients with MDD
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) LT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-003803-19 Sponsor Protocol Number: WXL101497 Start Date*: 2004-11-10
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydroch...
    Medical condition: Major Depressive Disorder (MDD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002640-25 Sponsor Protocol Number: 217-MDD-302 Start Date*: 2019-12-09
    Sponsor Name:Sage Therapeutics, Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DIS...
    Medical condition: MAJOR DEPRESSIVE DISORDER
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000229-19 Sponsor Protocol Number: 15905A Start Date*: 2014-09-19
    Sponsor Name:H. Lundbeck A/S
    Full Title: An interventional, randomised, double-blind, parallel-group, placebo-controlled study on the efficacy of vortioxetine on cognitive dysfunction in patients with partial or full remission of major de...
    Medical condition: Major Depressive Disorder and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) FI (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004440-29 Sponsor Protocol Number: ITI-007-403 Start Date*: 2020-05-21
    Sponsor Name:Intra-Cellular Therapies, Inc. (ITI)
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes...
    Medical condition: Major depressive episodes (MDEs) associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) with mixed features or major depressive disorder (MDD) with mixed features
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10004936 Bipolar depression LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-000719-26 Sponsor Protocol Number: ETS6103-003 Start Date*: 2013-06-10
    Sponsor Name:e-Therapeutics plc
    Full Title: A single centre, double blind, non-inferiority study to evaluate the antidepressant activity of Viotra™ compared with amitriptyline in the treatment of major depressive disorder (MDD) in patients w...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004409-24 Sponsor Protocol Number: AK130940 Start Date*: 2005-06-08
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150m...
    Medical condition: Major Depressive Disorder (MDD)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003992-23 Sponsor Protocol Number: 54135419SUI3002 Start Date*: 2017-07-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Sympto...
    Medical condition: Major Depressive Disorder with Imminent Risk of Suicide
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10042458 Suicidal ideation PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012397 Depression suicidal PT
    20.0 10037175 - Psychiatric disorders 10065604 Suicidal behaviour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) CZ (Completed) AT (Completed) LT (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-002126-24 Sponsor Protocol Number: SEP380-301 Start Date*: 2022-02-02
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ...
    Medical condition: Major Depressive Episode Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) SK (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001683-29 Sponsor Protocol Number: 61393215MDD2001 Start Date*: 2019-09-27
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-61393215 as Adjunctive Treatment in Adults with Major Depressive Disorder with Anxio...
    Medical condition: Adjunctive Treatment in Adults with Major Depressive Disorder with Anxious Distress with Suboptimal Response to Standard Antidepressants
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-005069-39 Sponsor Protocol Number: 10990 Start Date*: 2005-06-30
    Sponsor Name:H. Lundbeck A/S
    Full Title: A double-blind, randomised, multicenter, comparative study of escitalopram and duloxetine in outpatients with Major Depressive Disorder
    Medical condition: Major depressive disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DE (Completed) SE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 19:03:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA